The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges

Journal of Infectious Diseases

Volumn 216, Issue , 2017, Pages S702-S713

  Naidoo, Pren ^a,g   Theron, Grant ^a,b   Rangaka, Molebogeng X ^c,h   Chihota, Violet N ^d,e,g   Vaughan, Louise ^a,b   Brey, Zameer O ^g   Pillay, Yogan ^f  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b DST   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

^d AURUM INSTITUTE   (South Africa)

^e UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^f NATIONAL DEPARTMENT OF HEALTH   (South Africa)

^g BILL AND MELINDA GATES FOUNDATION   (United States)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

care cascade; case finding; continuum of care; initial loss to follow up; treatment success; Tuberculosis

Indexed keywords

RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; CLINICAL PROTOCOL; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE BURDEN; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MIXED INFECTION; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; SOUTH AFRICAN; TUBERCULOSIS; TUBERCULOSIS CONTROL; BLACK PERSON; COMMUNITY CARE; COMPLICATION; COST OF ILLNESS; DISEASE ERADICATION; DRUG EFFECTS; FOLLOW UP; INCIDENCE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TREATMENT OUTCOME;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; COINFECTION; COMMUNITY HEALTH SERVICES; COST OF ILLNESS; DISEASE ERADICATION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HIV INFECTIONS; HUMANS; INCIDENCE; LOST TO FOLLOW-UP; MYCOBACTERIUM TUBERCULOSIS; PATIENT CARE; RIFAMPIN; SOUTH AFRICA; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 85034449054     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jix335     Document Type: Conference Paper

References (65)

1. World Health Organization (WHO). Global tuberculosis report 2016. Geneva: WHO, 2016.
2. South African National Institute for Communicable Diseases. South African tuberculosis drug-resistance survey 2012-14. Johannesburg, South Africa: National Institute for Communicable Diseases, 2016. Available at: Http://www. nicd.ac.za/assets/files/K-12750%20NICD%20National%20Survey%20Report-Dev-V11-LR.pdf. Accessed 22 July 2017.
3. World Health Organization. The End TB Strategy. Geneva, Switzerland: WHO, 2015.
4. WHO TB burden estimates. Geneva, Switzerland: WHO, 2016. Available at: Http://www.who.int/tb/country/data/download/en/. Accessed 26 October 2016.
5. Bhardwaj S, Barron P, Pillay Y, et al. Elimination of mother-to-child transmission of HIV in South Africa: Rapid scale-up using quality improvement. S Afr Med J 2014; 104:239-43.
6. Dionne-Odom J, Welty TK, Westfall AO, et al. Factors associated with PMTCT cascade completion in four African countries. AIDS Res Treat 2016; 2016:2403936.
7. Woldesenbet S, Jackson D, Lombard C, et al.; South African PMTCT Evaluation (SAPMCTE) Team. Missed opportunities along the prevention of mother-to-child transmission services cascade in South Africa: Uptake, determinants, attributable risk (the SAPMTCTE). PLoS One 2015; 10:e0132425.
8. Takuva S, Brown AE, Pillay Y, Delpech V, Puren AJ. The continuum of HIV care in South Africa: Implications for achieving the second and third UNAIDS 90-90-90 targets. AIDS 2017; 31:545-52.
9. South African Government Communication and Information Systems. South Africa yearbook 2013/14. 2014, 203-25. Available at: Http://www.gcis.gov.za/content/resourcecentre/sa-info/yearbook2013-14.
10. Statistics South Africa. General Household Survey 2013-2014. South Africa: Statistics South Africa. Available at: Https://www.datafirst.uct.ac.za/dataportal/index.php/catalog/486. Accessed 26 February 2016.
11. TB Diagnostics Market Analysis Consortium. Market assessment of tuberculosis diagnostics in South Africa, 2012-2013. Int J Tuberc Lung Dis 2015; 19:216-22.
12. Steingart KR, Sohn H, Schiller I, et al. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2013; 1:CD009593.
13. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: A multicentre implementation study. Lancet 2011; 377:1495-505.
14. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: A systematic review. Lancet Infect Dis 2006; 6:570-81.
15. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: A meta-analysis. Eur Respir J 2008; 32:1165-74.
16. McCarthy KM, Grant AD, Chihota V, et al. Implementation and operational research: What happens after a negative test for tuberculosis? Evaluating adherence to TB diagnostic algorithms in South African primary health clinics. J Acquir Immune Defic Syndr 2016; 71:e119-26.
17. Churchyard GJ, Stevens WS, Mametja LD, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: A cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health 2015; 3:e450-7.
18. Botha E, den Boon S, Lawrence KA, et al. From suspect to patient: Tuberculosis diagnosis and treatment initiation in health facilities in South Africa. Int J Tuberc Lung Dis 2008; 12:936-41.
19. Botha E, Den Boon S, Verver S, et al. Initial default from tuberculosis treatment: How often does it happen and what are the reasons? Int J Tuberc Lung Dis 2008; 12:820-3.
20. Bristow CC, Dilraj A, Margot B, Podewils LJ. Lack of patient registration in the electronic TB register for sputum smear-positive patients in KwaZulu-Natal, South Africa. Tuberculosis (Edinb) 2013; 93:567-8.
21. Claassens MM, du Toit E, Dunbar R, et al. Tuberculosis patients in primary care do not start treatment. What role do health system delays play? Int J Tuberc Lung Dis 2013; 17:603-7.
22. Cox HS, Mbhele S, Mohess N, et al. Impact of Xpert MTB/RIF for TB diagnosis in a primary care clinic with high TB and HIV prevalence in South Africa: A pragmatic randomised trial. PLoS Med 2014; 11:e1001760.
23. Dunbar R, van Hest R, Lawrence K, et al. Capture-recapture to estimate completeness of tuberculosis surveillance in two communities in South Africa. Int J Tuberc Lung Dis 2011; 15:1038-43.
24. Cele LP, Knight S, Webb E, Tint K, Dlungwane T. High level of initial default among smear positive pulmonary tuberculosis in eThekwini health district, KwaZulu-Natal. South African J Infect Dis 2016; 53:1-3.
25. Van Den Handel T, Hampton KH, Sanne I, Stevens W, Crous R, Van Rie A. The impact of Xpert(® ) MTB/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis 2015; 19:392-8.
26. Hanrahan CF, Clouse K, Bassett J, et al. The patient impact of point-of-care vs. laboratory placement of Xpert(® ) MTB/RIF. Int J Tuberc Lung Dis 2015; 19:811-6.
27. Hanrahan CF, Selibas K, Deery CB, et al. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care Xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One 2013; 8:e65421.
28. Podewils LJ, Bantubani N, Bristow C, et al. Completeness and reliability of the Republic of South Africa National Tuberculosis (TB) Surveillance System. BMC Public Health 2015; 15:765.
29. Theron G, Zijenah L, Chanda D, et al.; TB-NEAT team. Feasibility, accuracy, clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: A multicentre, randomised, controlled trial. Lancet 2014; 383:424-35.
30. Voss De Lima Y, Evans D, Page-Shipp L, et al. Linkage to care and treatment for TB and HIV among people newly diagnosed with TB or HIV-associated TB at a large, inner city South African hospital. PLoS One 2013; 8:e49140.
31. Van Rie A, Page-Shipp L, Hanrahan CF, et al. Point-of-care Xpert® MTB/RIF for smear-negative tuberculosis suspects at a primary care clinic in South Africa. Int J Tuberc Lung Dis 2013; 17:368-72.
32. du Preez K, Schaaf HS, Dunbar R, et al. Incomplete registration and reporting of culture-confirmed childhood tuberculosis diagnosed in hospital. Public Heal Action 2011; 1:19-24.
33. R Development Core Team. R Statistical Computing 2017. R: A language and environment for statistical computing. Version 3.2.1. Vienna: R Foundation for Statistical Computing, 2017.
34. Cox H, Dickson-Hall L, Ndjeka N, et al. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. PLoS Med 2017; 14:e1002238.
35. Dye C, Watt CJ, Bleed DM, Williams BG. What is the limit to case detection under the DOTS strategy for tuberculosis control? Tuberculosis (Edinb) 2003; 83:35-43.
36. World Health Organization. Assessment of the fraction of cases being missed by routine TB notification data, based on the "Onion" model. 2009. Available at: Http://www.who.int/tb/advisory-bodies/impact-measurement-taskforce/meetings/ie-apr09-fracion-missed-en.pdf. Accessed 18 April 2017.
37. Subbaraman R, Nathavitharana RR, Satyanarayana S, et al. The tuberculosis cascade of care in India's public sector: A systematic review and meta-analysis. PLoS Med 2016; 13:e1002149.
38. Hossain ST, Isaakidis P, Sagili KD, et al. The multi-drug resistant tuberculosis diagnosis and treatment cascade in Bangladesh. PLoS One 2015; 10:e0129155.
39. Southern Africa Labour and Development Research Unit (SALDRU), School of Economics University of Cape Town. National Income Dynamics Study. Cape Town, 2013. Available at: Http://www.nids.uct.ac.za/nids-data/data-access.
40. World Health Organization. TB impact measurement policy and recommendations for how to assess the epidemiological burden of TB and the impact of TB control. Stop TB policy paper no. 2. 2009. Available at: Http://www.who.int/tb/publications/2009/impactmeasurementpolicy/en/. Accessed 9 October 2016.
41. Glaziou P, Sismanidis C, Zignol M, Floyd K. Methods used to estimate the global burden of disease caused by TB. Geneva, Switzerland: Global TB Program, World Health Organization, 2012. Available at: Http://www.who.int/tb/publications/global-report/gtbr2016-online-technical-appendix-global-disease-burden-estimation.pdf?ua=1. Accessed 1 April 2017.
42. Dye C. Breaking a law: Tuberculosis disobeys Styblo's rule. Bull World Health Organ 2008; 86:4.
43. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJ. Natural history of tuberculosis: Duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: A systematic review. PLoS One 2011; 6:e17601.
44. van Leth F, van der Werf MJ, Borgdorff MW. Prevalence of tuberculous infection and incidence of tuberculosis: A re-assessment of the Styblo rule. Bull World Health Organ 2008; 86:20-6.
45. Qin ZZ, Pai M, Van Gemert W, Sahu S, Ghiasi M, Creswell J. How is Xpert MTB/RIF being implemented in 22 high tuberculosis burden countries? Eur Respir J 2015; 45:549-54.
46. Skordis-Worrall J, Hanson K, Mills A. Confusion, caring and tuberculosis diagnostic delay in Cape Town, South Africa. Int J Tuberc Lung Dis 2010; 14:171-80.
47. Gilson L, Palmer N, Schneider H. Trust and health worker performance: Exploring a conceptual framework using South African evidence. Soc Sci Med 2005; 61:1418-29.
48. Goudge J, Gilson L, Russell S, Gumede T, Mills A. Affordability, availability and acceptability barriers to health care for the chronically ill: Longitudinal case studies from South Africa. BMC Health Serv Res 2009; 9:75.
49. Chimbindi N, Bärnighausen T, Newell ML. Patient satisfaction with HIV and TB treatment in a public programme in rural KwaZulu-Natal: Evidence from patientexit interviews. BMC Health Serv Res 2014; 14:32.
50. Harris B, Goudge J, Ataguba JE, et al. Inequities in access to health care in South Africa. J Public Health Policy 2011; 32(Suppl 1):S102-23.
51. Naidoo P, van Niekerk M, du Toit E, Beyers N, Leon N. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: A qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests. BMC Health Serv Res 2015; 15:488.
52. Skinner D, Claassens M. It's complicated: Why do tuberculosis patients not initiate or stay adherent to treatment? A qualitative study from South Africa. BMC Infect Dis 2016; 16:712.
53. Schulz SA, Draper HR, Naidoo P. A comparative study of tuberculosis patients initiated on ART and receiving different models of TB-HIV care. Int J Tuberc Lung Dis 2013; 17:1558-63.
54. Loveday M, Padayatchi N, Wallengren K, et al. Association between health systems performance and treatment outcomes in patients co-infected with MDR-TB and HIV in KwaZulu-Natal, South Africa: Implications for TB programmes. PLoS One 2014; 9:e94016.
55. Loveday M, Padayatchi N, Voce A, Brust J, Wallengren K. The treatment journey of a patient with multidrug-resistant tuberculosis in South Africa: Is it patient-centred? Int J Tuberc Lung Dis 2013; 17:56-9.
56. Birch S, Govender V, Fried J, et al. Does treatment collection and observation each day keep the patient away? An analysis of the determinants of adherence among patients with Tuberculosis in South Africa. Health Policy Plan 2016; 31:454-61.
57. Theron G, Peter J, Zijenah L, et al. Psychological distress and its relationship with non-adherence to TB treatment: A multicentre study. BMC Infect Dis 2015; 15:253.
58. Maswanganyi Nandzumuni V, Lebese Rachel T, Mashau Ntsieni S, Khoza Lunic B. Patient-perceived factors contributing to low tuberculosis cure rate at Greater Giyani healthcare facilities. Health SA Gesondheid 2014; 19:1-8. http://dx.doi. org/10.4102/hsag.v19i1.724. Accessed 15 May 2016.
59. Moyo S, Cox HS, Hughes J, et al. Loss from treatment for drug resistant tuberculosis: Risk factors and patient outcomes in a community-based program in Khayelitsha, South Africa. PLoS One 2015; 10:e0118919.
60. Loveday M, Wallengren K, Brust J, et al. Community-based care vs. centralised hospitalisation for MDR-TB patients, KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis 2015; 19:163-71.
61. World Health Organization (WHO). WHO treatment guidelines for drug-resistant tuberculosis. Geneva, Switzerland: WHO, 2016.
62. Health Systems Trust. District health barometer 2014/2015. 2015. Available at: Http://www.hst.org.za/publications/District%20Health%20Barometers/Complete-DHB-2014-15-linked.pdf. Accessed 6 October 2016.
63. Shah NS, Auld SC, Brust JC, et al. Transmission of extensively drug-resistant tuberculosis in South Africa. N Engl J Med 2017; 376:243-53.
64. Sreeramareddy CT, Panduru KV, Menten J, Van den Ende J. Time delays in diagnosis of pulmonary tuberculosis: A systematic review of literature. BMC Infect Dis 2009; 9:91.
65. Storla DG, Yimer S, Bjune GA. A systematic review of delay in the diagnosis and treatment of tuberculosis. BMC Public Health 2008; 8:15.